Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Recommendation of “Moderate Buy” by Analysts

Kodiak Sciences Inc. (NASDAQ:KOD) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $42.1429.

Several research firms have commented on KOD. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $14.00 to $61.00 in a research report on Monday, May 11th. UBS Group upped their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 27th. Wall Street Zen upgraded shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research report on Friday, March 27th.

Institutional Trading of Kodiak Sciences

A number of institutional investors have recently made changes to their positions in KOD. Westfuller Advisors LLC bought a new stake in shares of Kodiak Sciences in the 1st quarter worth approximately $26,000. V Square Quantitative Management LLC acquired a new stake in shares of Kodiak Sciences during the first quarter valued at approximately $26,000. EverSource Wealth Advisors LLC raised its holdings in shares of Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Kodiak Sciences during the fourth quarter valued at approximately $29,000. Finally, Headlands Technologies LLC raised its holdings in shares of Kodiak Sciences by 256.4% during the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after acquiring an additional 5,815 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Trading Down 3.2%

NASDAQ KOD opened at $36.23 on Friday. Kodiak Sciences has a 52 week low of $3.26 and a 52 week high of $47.84. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -8.69 and a beta of 2.32. The company has a 50-day moving average price of $37.49 and a two-hundred day moving average price of $29.01.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, May 7th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.01). As a group, equities research analysts expect that Kodiak Sciences will post -3.89 earnings per share for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.